20/15 Visioneers reported that Mimrylo (rusfertide) cleared August 28 as the first hepcidin-mimetic for polycythemia vera.
Public source
Publisher name
Public post
🧬 Science & Technology Weekly: Four FDA Firsts in Four Days, and a 135-Day Review The FDA announced a first-in-class or first-indication clearance on four consecutive w…
Company
20/15 Visioneers
Better Vision=Better Outcomes Bringing the holistic approach to Science with Culture/Data/Process/Technology
- Industry
- Information Technology & Services
- Location
- HEREFORD, US
- Company size
- 11–50 employees
About 20/15 Visioneers
20/15 Visioneers was founded on the principle of providing the best possible value in scientific informatics. We believe there is a cadence to doing this right and have many case studies to prove our effectiveness. Before investing millions of dollars in software, hardware, and possibly inefficient work practices you might want to listen to what we have to say. Hands-on experience (actual work and strategy) with not only R&D but also scientific data foundations, imaging, predictive (suggestive) science and much-needed change management. Currently helping clients with their R&D digitization, electronic laboratory environments and clinical research informatics needs. We serve biotech, biopharma, materials, chemicals, oil and gas, food and consumer packaged goods. We can help you in important roles on an interim basis by getting structure in place and the proper logistics to hire and scale the organization.
See moreLatest activity
Latest activity from 20/15 Visioneers
12 signals
Presence & Recognition
20/15 Visioneers announced that HitchhikersAI is a company.
Presence & Recognition
20/15 Visioneers announced HitchhikersAI as a new product.
Research & Knowledge
20/15 Visioneers reported that Gilead's Bixlenvo was approved the same week as Mimrylo (rusfertide) cleared, a company succeeding its own standard of care.
Discover more
Similar signals
Similar public activity from other companies.
Legal & Regulatory
MPN Research Foundation
MPN Research Foundation reported that the FDA has approved Mimrylo (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera.
Research & Knowledge
OncologyTube.com
OncologyTube.com reports that MIMRYLO for erythrocytosis in adults with polycythemia vera received FDA approval, with 76.9% of patients meeting the response in weeks 20-32.
Legal & Regulatory
Spherix Global Insights
Spherix Global Insights reported that the FDA approved MIMRYLOâ„¢, the first hepcidin mimetic for adults with polycythemia vera, introducing a new way to control hematocrit while reducing the need for phlebotomy and improving fatigue.
Legal & Regulatory
HealthTree Foundation
HealthTree Foundation reported that on August 31, 2026, the FDA approved ropeginterferon alfa-2b-njft (Besremi) for the treatment of adults with essential thrombocythemia (ET).
Legal & Regulatory
MedChemExpress LLC